Abstract
Nivolumab plus ipilimumab (N+I) therapy has shown promising antitumor efficacy and safety for advanced hepatocellular carcinoma (HCC) patients after sorafenib therapy. This study aimed to explore whether N+I may improve the treatment efficacy of HCC patients who are potentially eligible for curative surgery (NCT03510871).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
